Teva新的可注射精神分裂症(UZEDY)的复发率比每天服用的药丸低,住院次数也少。 Teva's new schizophrenia injectable, UZEDY, shows lower relapse rates and fewer hospital visits than daily pills.

Teva制药公司提供了新的数据,表明UZEDY是一种对精神分裂症的注射治疗,与日常口服药物相比,复发率较低,患者结果较好。 Teva Pharmaceuticals presented new data showing that UZEDY, an injectable treatment for schizophrenia, has lower relapse rates and better patient outcomes compared to daily oral medications. 数据还表明,使用UZEDY的病人住院次数较少,医疗费用也较低。 The data also indicates that patients using UZEDY had fewer hospital visits and lower healthcare costs. 此外,第3阶段对可注射新阿兰扎平剂的试验显示,没有发生被称为注射后痢疾/沉睡综合症的副作用案例。 Additionally, Phase 3 trials for a new olanzapine injectable showed no cases of a concerning side effect known as post-injection delirium/sedation syndrome.